A Study to Investigate ALE.P02 as Monotherapy in Adult Patients With Selected CLDN1+ Solid Tumors
A phase 1/2 trial of ALE.P02 in non-small-cell lung cancer, head and neck squamous cell carcinoma and oesophageal cancer, run by Alentis Therapeutics AG, now recruiting.
Overview
A Study to Investigate ALE.P02 as Monotherapy in Adult Patients With Selected CLDN1+ Solid Tumors is a phase 1/2 interventional study registered as NCT06747585 by Alentis Therapeutics AG, with 170 participants planned, started 2024-12-16 and due to reach its primary completion in 2028-02-15. Interventions recorded: ALE.P02.
Similar pages
not linked directly; found by shared links- TrialA Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors
Shares Alentis Therapeutics, Non-small-cell lung cancer and the tag pipeline.
- TrialA Study of IDP-001 in Advanced or Metastatic Solid Tumors
Shares Oesophageal cancer, Head and neck squamous cell carcinoma, Non-small-cell lung cancer and the tag pipeline.
- TrialA Study to Investigate the Safety, Pharmacokinetics, and Clinical Activity of AP203 in Patients with Locally Advanced or Metastatic Solid Tumors, and Expansion to Selected Malignancies
Shares Oesophageal cancer, Head and neck squamous cell carcinoma, Non-small-cell lung cancer and the tag pipeline.
- TrialA Study of MT-4561 in Patients With Various Advanced Solid Tumors
Shares Oesophageal cancer, Head and neck squamous cell carcinoma, Non-small-cell lung cancer and the tag pipeline.
- TrialA Study of DM005 in Patients With Advanced Solid Tumors
Shares Head and neck squamous cell carcinoma, Non-small-cell lung cancer and the tag pipeline.
- TrialIntratumoral N17350 in Advanced Solid Tumors
Shares Head and neck squamous cell carcinoma, Non-small-cell lung cancer and the tag pipeline.
- TrialPhase 1/2 Study to Evaluate TH9619 in the Treatment of Advanced Solid Tumors
Shares Head and neck squamous cell carcinoma, Non-small-cell lung cancer and the tag pipeline.
- TrialA Study of GI-108, an Anti-CD73-IgG4 Fc-IL-2v Bispecific Fusion Protein, as Monotherapy in Patients With Advanced or Metastatic Solid Tumors
Shares Head and neck squamous cell carcinoma, Non-small-cell lung cancer and the tag pipeline.